Abstract
Objective To investigate the differential effects of frailty on biventricular function in senile patients and analyse the prognosis of different combinations of clinical status.
Methods and Results Patients aged ≥80 years with at least one basic disease causing heart failure were included and divided into three groups according to frailty score. Basic data, ultrasound data, and follow-up data were collected and analyses of differences between groups and survival were performed. The proportion of patients with right heart failure in the frailty group was significantly higher than that in the others. A total of 33 (15.1%) patients died within a year, 162 (74%) were readmitted within 1 year, and 84 (38.4%) were admitted for heart failure within 1 year. The frailty group with right heart failure had the highest rate of all cause and heart failure-related readmission. Frailty significantly increased the risk of 1-year all-cause mortality, all-cause readmission, and heart failure-related readmission. Right heart failure significantly increased the 1-year all-cause readmission and heart failure-related readmission rates. After adjusting for the interaction of factors, only frailty had a significant effect on the three prognostic events.
Conclusions Right heart failure is more likely to be associated with frailty in senile patients. One-year all-cause mortality, all-cause readmission, and heart failure-related readmission rates were significantly increased in frail patients with right heart failure.
Frailty was a significant predictor of all-cause death, all-cause readmission, and heart failure-related readmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Health research project for cadres of Sichuan Province, No. 2020-202 Scientific Research Fund of Sichuan Provincial Health Commission, No. 17PJ018 Key R&D Project of Science and Technology Department of Sichuan Province, No. 2020YFSY0045
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the Ethics Committee of Sichuan Provincial People's Hospital (ethical approval document No. 382, 2020)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
First author: Jiang Jing (e-mail: 340666917{at}qq.com)
Co-first author: Yang Baojun (e-mail: nevery{at}126.com)
Other authors’ information: Zhiying Zhao (e-mail: zhaozhiying2001{at}sina.com),
Xie Dili (e-mail: 1809009521{at}qq.com),
Zhang Yunhe (e-mail: 38801570{at}163.com),
Yu Rong (e-mail: 348767213{at}qq.com),
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.